Company profile: Peptomyc
1.1 - Company Overview
Company description
- Provider of next-generation cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. Built on Dr. Soucek’s Omomyc research, the company’s lead candidate, OMO-103, is an Omomyc-derived therapeutic peptide designed to inhibit the deregulated Myc oncoprotein in many cancers to halt tumor growth and progression. Founded in December 2014.
Products and services
- OMO-103: A peptide-based therapeutic derived from Omomyc, engineered to inhibit the Myc oncoprotein deregulated in many cancers, aiming to halt tumor growth and progression
- Cell-Penetrating Peptides (CPPs): Peptomyc architects a new generation of cell-penetrating therapeutics targeting the Myc oncoprotein for cancer treatment, grounded in Omomyc research
- Omomyc Research Program: An Omomyc-based, direct-Myc-inhibition research effort over twenty years by Dr. Soucek, establishing the best direct Myc inhibitor known to date
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Peptomyc
Myelo Therapeutics
HQ: Germany
Website
- Description: Provider of treatments addressing high unmet medical needs, focused on developing myelo001, a small molecule effective on hematogenesis and investigated for its oral application in treating chemotherapy-induced myelosuppression, radiation-induced myelosuppression, and acute radiation syndrome. Founded in 2013 and based in Berlin, Germany.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Myelo Therapeutics company profile →
MTM Laboratories
HQ: Germany
Website
- Description: Provider of ISO 9001 and 13485 certified in-vitro diagnostics for early detection and diagnosis of cervical and other cancers; headquartered in Heidelberg, Germany, with subsidiaries in the United States, France, Italy and Spain; markets proprietary CINtec Histology Kit and CINtec.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MTM Laboratories company profile →
Auron Therapeutics
HQ: United States
Website
- Description: Provider of cancer therapeutics focused on transforming malignant cells toward more normal function. Offerings include AURIGIN, an AI/ML platform to identify and target drivers of tumor cell plasticity and altered cellular states in cancer, and AUTX-703, an orally available small molecule therapy targeting KAT2A/B for small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Auron Therapeutics company profile →
Valerio Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology therapeutics leveraging the platON chemistry platform to generate DNA-decoy compounds targeting intracellular DNA-binding proteins for tumors and inflammatory diseases; develops AsiDNA and VIO-01 to disrupt DNA repair and activate the STING pathway, and Belinostat/Beleodaq, a histone deacetylase inhibitor for hematological and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valerio Therapeutics company profile →
Pelican Therapeutics
HQ: United States
Website
- Description: Provider of next-generation TNF-based immunotherapy biologic agents, focused on developing and commercializing monoclonal antibody and fusion protein therapies designed to activate the immune system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pelican Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Peptomyc
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Peptomyc
2.2 - Growth funds investing in similar companies to Peptomyc
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Peptomyc
4.2 - Public trading comparable groups for Peptomyc
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →